Diabetes is a modern-day epidemic in the making, but drug developers are still undecided over the best strategy for its treatment.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Data taken from US Centers for Disease Control web site, http://www.cdc.gov/diabetes.
American Diabetes Association. Economic consequences of diabetes mellitus in the US in 1997. Diabetes Care 21, 296–309 (1998).
Knowler, W.C. et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346, 393–403 (2002).
Barroso, I. et al. Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 402, 880–883 (1999).
Fletcher, L. Oral insulin deal for Nobex. Nat. Biotechnol. 20, 645 (2002).
Steppan, C.M. et al. The hormone resistin links obesity to diabetes. Nature 409, 307–312 (2002).
Sesti, G. Searching for type 2 diabetes genes: prospects in pharmacotherapy. Pharmacogenomics J. 2, 25–29 (2002).
Lumelsky, N. et al. Differentiation of embryonic stem cells to insulin-secreting structures similar to pancreatic islets. Science 292, 1389–1394 (2001).
Rights and permissions
About this article
Cite this article
Dove, A. Seeking sweet relief for diabetes. Nat Biotechnol 20, 977–981 (2002). https://doi.org/10.1038/nbt1002-977
Issue Date:
DOI: https://doi.org/10.1038/nbt1002-977
This article is cited by
-
Erratum: Seeking sweet relief for diabetes
Nature Biotechnology (2003)